Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Gastrointestinal 2Thoracic 1NET 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Neuroendocrine Tumors 143Carcinoma, Neuroendocrine 56Thyroid Cancer, Papillary 54Pheochromocytoma 50Thyroid Neoplasms 41Paraganglioma 41Pituitary Neoplasms 37Adrenocortical Carcinoma 31Neoplasms 30Multiple Endocrine Neoplasia Type 1 29Gastro-enteropancreatic neuroendocrine tumor 29Thyroid Carcinoma, Anaplastic 23Small Cell Lung Carcinoma 21Lung Neoplasms 21Carcinoid Tumor 20Sarcoma 19Breast Neoplasms 19Neoplasm Metastasis 18Carcinoma, Non-Small-Cell Lung 18Adenoma, Islet Cell 18Melanoma 17Carcinoma, Hepatocellular 17Prostatic Neoplasms 15Pancreatic Neoplasms 15Ovarian Neoplasms 15Neuroblastoma 15Colorectal Neoplasms 15Carcinoma, Renal Cell 15Adrenal Gland Neoplasms 15Adenocarcinoma, Follicular 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Piebaldism × Endocrine × 1 year × Clear all
NCT06805825 2025-09-23

A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

Novelty Nobility, Inc.

Phase 1 Recruiting
67 enrolled
DermatologicEndocrineGastrointestinalGenitourinaryNETSarcomaThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Carcinoma, Adenoid Cystic, Piebaldism, Neuroendocrine Tumors, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡